Purpose: Metabolic activity, as defined by 18 F-FDG uptake on PET, is a prognostic marker for multiple malignancies; however, no study has examined the prognostic value of imaging with FDG PET in stage I and II pancreatic cancer. We examined the value of PET FDG uptake in early-stage pancreatic cancer patients. Methods: We identified patients with early-stage pancreatic cancer (I-II) who had FDG PET scan performed as part of their preoperative evaluation. The patients were divided into either high or low FDG uptake according to the median primary tumor standard uptake value (SUVmax). Our primary end points were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier estimate was used for survival analysis. Pathologic data were compared using the Fisher exact and χ 2 tests. Results: One hundred five patients were identified: 51 patients with low FDG uptake and 54 patients with high FDG uptake. Eighty-five patients (81%) had PET avid tumors, whereas 20 (19%) patients did not. High FDG uptake correlated with pathologic stage (P = 0.012). Patients with low FDG uptake had significantly better median OS than patients with high FDG uptake (28 vs. 16 months; P = 0.036). Patients with low-FDG uptake had significantly longer median RFS than patients with high FDG uptake (14 vs. 12 months; P = 0.049). Conclusions: Low FDG uptake in PET scans in patients with stage I and II pancreatic cancer correlates with improved OS and RFS. This supports the concept that glucose metabolic pathways are important in pancreatic cancer biology and that PET scan activity can be used as a prognostic biomarker after pancreatectomy.
M etabolic activity, as defined by the uptake of 18 F-FDG on PET, takes advantage of the physiologic preferential use of anaerobic glycolysis over oxidative phosphorylation used by malignant cells for their energetic needs. 1, 2 This phenomenon, known as the Warburg effect, has recently been revived with the clinical use of PET and verified with the tracer FDG. 3 A higher rate of ATP generation is observed if cellular respiration occurs through glycolysis, enabling cancer cells to gain a competitive advantage for shared energy resources such as glucose. 3 Given that cancer cells use an increased need for glucose and that FDG, an analog of glucose, can be used with PET imaging, the increased uptake of FDG on PET can potentially be associated with a poor prognosis in patients with early-stage pancreatic cancer. Imaging of FDG with PET has also been used successfully as a diagnostic and prognostic marker for multiple malignancies and is used routinely in the workup and follow-up of a number of different diseases, including advanced malignant melanoma, esophageal cancer, lung cancer, and breast cancer. [4] [5] [6] [7] [8] [9] [10] Anticancer therapies that target glucose metabolism in cancer cells have also been recently investigated. 3 Current guidelines for the staging and follow-up of pancreatic cancer do not include PET as a method for diagnosis or staging for this disease. 11 However, our group reported a 10% rate of upstaging in patients with a condition diagnosed as resectable pancreatic cancer by including a PET scan in their staging workup, leading to changes in the testing of our pancreatic cancer patients. 12 Others have assigned importance in the evaluation of hypermetabolic lesions in patients with cystic lesions of the pancreas, [13] [14] [15] and reports have been published regarding the value of FDG uptake as a marker of response to definitive chemoradiation in patients with locally advanced pancreatic carcinoma. 16 However, no study has examined the prognostic value of PET in stage I and II pancreatic cancer. Therefore, in light of these previous reports, our goal was to evaluate the prognostic value of hypermetabolic activity as indicated by FDG uptake in patients with a diagnosis of early pancreatic cancer, to help inform on the possible value of PET in this lethal disease.
PATIENTS AND METHODS

Patients
In 2005, after institutional review board approval, the gastrointestinal oncology department at Moffitt Cancer Center established a database of pancreatic cases by performing a retrospective chart review of patients operated on at Moffitt starting as far back as 1987, which has continued to this date. Data collected for this database include patient demographics, preneoadjuvant treatment clinical assessment, postneoadjuvant treatment clinical assessment, surgical procedure details, pathological tumor stage and histopathologic features, perioperative events, and complications. The diagnosis of pancreatic cancer was confirmed by pathological analysis of a surgical specimen in patients with resectable disease. Chart reviews were performed solely by experienced clinicians and recorded on standardized abstraction forms. Data were entered into a Microsoft Access database by a data analyst, and ambiguities in any data points were discussed, researched, reviewed, and corrected. We queried this database for patients who had undergone operations at Moffitt between February 2004 and December 2010, focusing on those patients who had PET scans or were available for review as part of the preoperative staging workup. This study focused on patients with stage I and II pancreatic ductal adenocarcinoma, and treatment of patients was according to National Comprehensive Cancer Network guidelines. 11 In brief, all patients had curative surgical resection and adjuvant chemotherapy and chemoradiation therapy. All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975 as revised in 2005.
Surgical Procedures
Surgical procedures included standard pancreaticoduodenectomy for tumors of the head and uncinate process and distal pancreatectomy and splenectomy for tumors of the neck, body, and tail. For vascular reconstruction, when needed, we used the internal saphenous vein, harvested from the groin of the patients. The patients were seen in clinic approximately 1 month after surgery if they had any surgical procedure and then every 3 to 4 months thereafter as described before. 16 
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F-FDG PET Protocol and Analysis
For FDG PET scans in patients with pancreatic cancer who are scheduled for resective surgery at our institution, nondiabetic patients are asked to fast for at least 4 hours and diabetic patients are asked to fast for at least 6 hours before scanning. Blood glucose concentrations are measured to ensure that glucose levels do not exceed 200 mg/dL before intravenous injection of FDG. There is then approximately a 90-minute interval between administration of 10-mCi FDG intravenously and the acquisition of the emission images to ensure adequate biodistribution of FDG. The average scan time is 3 minutes per bed, with there being 7 or 8 beds total. The normal slice thickness is 3.75 mm. We perform FDG studies with a dedicated PET/CT scanner, the GE-Discovery DVCT-PET/ CT (GE Medical Systems, Milwaukee, WI), which has a 70-cm aperture, 15-cm axial field of view, a 64-slice CT scanner, and a LYSO crystal-based PET scanner. This scanner includes a BGO block detector system and has a crystal size of 4.7 mm transaxially, 6.3 mm axially, and 30 mm radially. The axial sampling interval is 3.27 mm. Positron emission tomography images are reviewed by a boardcertified nuclear medicine physician, and tumors are defined as having positive FDG uptake if the radioactivity of the tumor is higher than that of the surrounding tissue in visual analyses. Images are then assessed semiquantitatively by measuring and calculating the median primary tumor standard uptake value (SUVmax) normalized to lean body mass.
Statistical Analysis
In our analyses, we found that the median SUVmax by the pancreatic tumors was 5.1 (0-27.1). We decided to base our analyses around this median SUVmax and thus divided patients into those with high FDG uptake (>median SUVmax) and those with low FDG uptake. For analysis, we used the χ 2 or the Fisher exact test as appropriate for categorical data, and mean differences were examined for continuous data using analysis of variance. All statistical tests performed were two sided and declared at the 5% significance level. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). Overall survival was calculated from the date of surgery until the date of death or last contact. Recurrence-free survival was calculated from the date of surgery until the last date at which the patient was known to be free of disease. Overall survival and RFS curves were created by the Kaplan-Meier method. Statistical analyses were performed with STATA 10 (Stata Statistical Software, Release 10.0; Strata Corp., College Station, TX).
RESULTS
Clinicopathological Characteristics of Patients
We identified 164 patients who underwent pancreatic resection for histologically proven pancreatic adenocarcinoma stage I and II. Of these patients, 105 had PET scans performed as part of their preoperative staging workup and were available for review (mean age at diagnosis of 67 [24-89] years, with 60 male patients [57%]). Eighty-five patients (81%) displayed PET avid tumors, whereas lack of FDG uptake was seen in 20 patients (19%) (Fig. 1) . The median PET SUVmax was 5.1 (0-27.1). Based on this value, we divided patients into 2 groups: low FDG and high FDG uptake, with 51 patients having low FDG uptake and 54 patients having high FDG uptake. When we compared the 2 groups, we found no statistically significant differences in sex, tumor grade, or nodal stage, although significance was almost reached for T stage (Table 1) . However, we found that low uptake was correlated with lower overall pathologic stage than high uptake. At our institution, we only use neoadjuvant therapy for patients with borderline resectable tumors as defined by the AHPBA and the National Comprehensive Cancer Network. 11 When assessing our data, we found that administration of neoadjuvant and adjuvant chemotherapy was not different for the low-FDG versus high-FDG uptake groups.
FDG PET Uptake Correlates With OS and RFS
We found that OS was correlated with preoperative PET FDG uptake, which was 28 months (95% confidence interval [CI], 22-32 months) in patients with low FDG vs. 16 months (95% CI, 10-21 months) (P = 0.036) in high-FDG uptake patients (Fig. 2) . Recurrence-free survival was 14 months (95% CI, 10.9-17 months) vs. 12 months (95% CI, 10-21 months) (P = 0.049) ( Fig. 3) in low-and high-FDG patients, respectively. Median follow-up of patients was 12.3 months (0-56 months). Moreover, on multiple regression analysis, we found that high FDG uptake (hazard ratio [HR], 2.1; 95% CI, 1.59-5; P = 0.02) and poor histologic differentiation (HR, 2.1; 95% CI, 1.1-4.1; P = 0.014) were independent factors associated with decreased survival in this cohort of patients. Although stage IIB was associated with decreased survival, it did not reach statistical significance in this analysis ( Table 2) .
DISCUSSION
Pancreatic cancer is the fourth leading cause of cancer death, 17 with a dismal 5-year survival after surgical resection for patients who have early-stage (stages I-II) disease. Although pancreatectomy is plagued by high morbidity, it is the only curative option for this disease. [17] [18] [19] Efforts are underway to identify biomarkers that will predict patients with favorable tumor biology who would benefit the most from surgical treatment as well as to identify patients in which pancreatectomy would be associated with a suboptimal survival benefit. 20, 21 In this regard, markers such as elevated blood levels of Ca19-9 predict low resectability rate and poor survival rates. 21, 22 Positron emission tomography SUV in pancreatic adenocarcinoma patients may also prove to be useful as a biomarker for evaluation of OS and RFS, providing information to help guide surgical and medical management of these patients.
In other malignant diseases, FDG uptake has been used as a biomarker, 23 including in a study that showed increased metabolic uptake in pretreatment assessments correlated with worse response to chemoradiation in locally advanced hepatocellular carcinoma. 24 In 2009, Lee et al proposed that a high SUVmax in patients with hepatocellular carcinoma who underwent liver transplantation was the most significant predictor of recurrence, with similar findings seen by others. 25, 26 The degree of hypermetabolism was also shown to correlate with outcomes and response to treatment in patients with 14, 15, [27] [28] [29] [30] In this context, we found that patients who had low FDG uptake in PET scans for stage I and II pancreatic cancer showed improved OS and RFS when compared with patients who had high FDG uptake. Moreover, although significance was not reached (P = 0.3) when we examined the 19% of patients who had no FGD uptake, there was a trend toward improved outcomes in PET-negative patients, as median OS was not reached versus that shown in patients who had any FDG uptake (median OS of 21 months [95% CI, 13-28 months). This observation supports the concept that glucose metabolic pathways are important in pancreatic cancer biology and that preoperatively, PET scan activity can be used as a prognostic biomarker after pancreatectomy in patients with pancreatic cancer. It also brings to the forefront the fact that not all pancreatic adenocarcinomas are metabolically active and forewarns the use of the lack of FDG uptake as a marker of benign disease. The high percentage of PET-negative tumors in our study, which seems to be higher than other groups, further makes it unlikely that negative PET activity alone is enough to rule out cancer. Our study has several limitations: first that it is a database review and also that the PET scans were performed over a large period of time (2004) (2005) (2006) (2007) (2008) (2009) (2010) . We aimed to overcome these limitations by performing a review of each PET scan on the same software by the same reviewer. Our main strength is that most of our resected patients over this period of time, 105 of 164, underwent PET scanning as part of our institution's staging workup, allowing us to define patterns of glucose uptake in pancreatic cancer and also to evaluate small differences in the low-and high-uptake groups.
In conclusion, we demonstrated that low FDG uptake in PET scans for stage I and II pancreatic cancer correlates with improved OS and disease-free survival. This supports the notion that glucose metabolic pathways have a role in pancreatic cancer biology and that PET scan activity may be used as a prognostic tool after pancreatectomy in patients with pancreatic cancer. Our study further suggests that patients with high FDG uptake may need to be considered as high-risk individuals when making a decision to perform pancreatectomies in patients with early pancreatic cancer. This alternative prognostic tool may help to determine those patients who will benefit the most from surgical resection. 
